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Purpose
The treatment outcome of brentuximab vedotin (BV) has not been related with CD30 expre-
ssion in previous studies enrolling patients with a wide range of CD30 expression level.
Thus, this study explored the efficacy of BV in high-CD30–expressing non-Hodgkin lym-
phoma (NHL) patients most likely to benefit.  
Materials and Methods
This phase II study (Clinicaltrials.gov: NCT02280785) enrolled relapsed or refractory high-
CD30–expressing NHL, with BV administered intravenously at 1.8 mg/kg every 3 weeks.
The primary endpoint was > 40% disease control rate, consisting of complete response
(CR), partial response (PR), or stable disease. We defined high CD30 expression as ! 30%
tumor cells positive for CD30 by immunohistochemistry.
Results
High-CD30-expressing NHL patients (n=33) were enrolled except anaplastic large cell lym-
phoma. The disease control rate was 48.5% (16/33) including six CR and six PR; six patients
(4CR, 2PR) maintained their response over 16 completed cycles. Response to BV and sur-
vival were not associated with CD30 expression levels. Over a median of 29.2 months of
follow-up, the median progression-free and overall survival rates were 1.9 months and 6.1
months, respectively. The most common adverse events were fever (39%), neutropenia
(30%), fatigue (24%), and peripheral sensory neuropathy (27%). In a post-hoc analysis for
the association of multiple myeloma oncogene 1 (MUM1) on treatment outcome, MUM1-
negative patients showed a higher response (55.6%, 5/9) than MUM1-positive patients
(13.3%, 2/15).  
Conclusion
BV performance as a single agent was acceptable in terms of disease control rates and tox-
icity profiles, especially MUM1-negative patients.
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Introduction
Brentuximab vedotin (BV) is an anti-CD30 monoclonal 
antibody conjugated with the microtubule-disrupting agent
monomethyl auristatin E [1]. CD30, a transmembrane glyco-
protein, is uniformly expressed in Hodgkin lymphoma (HL)
and anaplastic large cell lymphoma (ALCL). BV has been
previously approved for the treatment of relapsed or refrac-
tory HL and systemic ALCL based on its high objective res-
ponse rates of 75% and 86% in relapsed or refractory HL and
systemic ALCL, respectively [2,3]. Subsequent to that appro-
val, the efficacy of BV was evaluated in various subtypes of
non-Hodgkin lymphoma (NHL), including diffuse large 
B-cell lymphoma (DLBCL), primary mediastinal B-cell lym-
phoma (PMBCL), peripheral T-cell lymphoma (PTCL), myco-
sis fungoides (MF), and various cutaneous T-cell lymphomas
[4-8]. All of these studies enrolled patients with a wide range
*A list of author’s a!liations appears at the
end of the paper.
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of CD30 expression levels, and their response rates were 
unrelated to CD30 expression level of tumor cells. For exam-
ple, 70% of patients with cutaneous T-cell lymphomas, inclu-
ding MF, responded to BV, and the different cutoff values 
(< 10%, 10%-50%, and ! 50%) were unrelated to response rate
in MF, although patients with < 5% CD30 expression had a
lower response likelihood compared with patients with ! 5%
expression [4,5]. The response rate to BV was also unrelated
with the level of CD30 expression in DLBCL (44%) and PTCL
(41%), and these response rates were higher in PMBCL pati-
ents (13.3%) even though PMBCL is typically characterized
by high CD30 expression [6-8]. Accordingly, these previous
studies enrolling patients with a wide range of CD30 expres-
sion levels may not provide sufficiently robust information
on the association between CD30 expression and response to
BV. Thus, we designed a phase II study to evaluate the effi-
cacy of BV as a salvage therapy in relapsed or refractory pati-
ents with high-CD30–expressing NHL other than ALCL.
Although a precise definition of high CD30 expression has
not been established, we defined cases having ! 30% of
CD30-positive tumor cells as high-CD30–expressing NHL
considering previous studies have used 10% to 20% of CD30-
positive tumor cells as the cutoff values for CD30 expression
across various subtypes of NHL [9-12].
CD30, a member of the tumor necrosis factor receptor 
superfamily, is known to exert a variety of biological func-
tions, including cell cycle regulation, apoptosis, and activa-
tion of nuclear factor !-light-chain-enhancer of activated B
cells (NF-!B). CD30 is preferentially expressed in activated
B cells; however, T and natural killer (NK) cells are also 
reported to express CD30 [13]. In addition, Epstein-Barr virus
(EBV) infection-associated lymphomas could express CD30
because latent membrane protein 1, a critical element of EBV
infection, may promote CD30 expression [14]. Accordingly,
previous studies have shown approximately 40% of CD30
expression in extranodal natural killer/T-cell lymphoma
(ENKTL), in which latent membrane protein 1 is commonly
expressed [15,16]. CD30 expression is also associated with
activation of interferon regulatory factor 4, also known as
multiple myeloma oncogene 1 (MUM1), because CD30 acti-
vation may promote activities of the NF-!B leading to MUM1
expression [17]. This positive feedback signaling from CD30
to MUM1 might contribute to tumor aggressiveness, because
MUM1 binds directly to the MYC promoter region leading
to cell proliferation [18,19]. Thus, EBV positivity and MUM1
expression of lymphoma cells may influence response to BV
due to their close relationship with CD30 expression.
We analyzed response rates in accordance with CD30 pos-
itivity and presented the results of this study after the com-
pletion of enrollment at the annual meeting of American
Society of Hematology in 2017 [20]. For this final report, we
re-evaluated the pathology subtypes and performed the post-
hoc analysis evaluating the associations of EBV positivity and
MUM1 expression with response to BV and survival out-
come to find biomarkers. We also re-evaluated the treatment
response to determine the interpatient heterogeneity of res-
ponse as a post-hoc analysis, and updated the survival status
on November 30, 2018.
Materials and Methods
1. Study design
This phase 2, open-label, multicenter study was designed
to evaluate the efficacy and safety of BV in patients with rela-
psed or refractory high-CD30–expressing NHL other than
ALCL. All subtypes of NHL including mature B-, T-, or NK-
cell lymphomas except ALCL were eligible for enrollment.
Because all patients were initially diagnosed with NHL 
before 2017, NHL subtype was classified based on the World
Health Organization’s 2008 criteria. The primary study 
objective was to determine the overall rate of disease control,
defined as complete response (CR), partial response (PR),
and stable disease (SD). Secondary objectives included deter-
mining toxicity profiles, progression-free survival (PFS), and
overall survival (OS). Patients received 1.8 mg/kg BV intra-
venously every 3 weeks. Those who achieved SD or better
continued to receive treatments up to a maximum of 16 
cycles. However, in the event of progressive disease (PD) or
unacceptable toxicity, BV administration should be discon-
tinued; dose reduction to 1.2 mg/kg and treatment delay up
to 3 weeks was allowed, depending on the type and severity
of toxicity, including peripheral neuropathy. Blood transfu-
sion or granulocyte colony-stimulating factors were allowed
for patients with anemia, thrombocytopenia, and neutrope-
nia. Response evaluation was completed by the investigator
according to the 2007 Revised International Working Group
Response Criteria for Malignant Lymphoma [21]. Baseline
assessment was performed by using computed tomography
(CT) and fluorine-18 deoxyglucose (FDG) positron emission
tomography/computed tomography (PET/CT) of the neck,
chest, abdomen, and pelvis prior to the first treatment cycle.
Restaging assessment was performed by CT and PET/CT
after the second cycle. Additional response evaluations for
preexisting lesions were evaluated after the fourth, eighth,
twelfth, and sixteenth cycles by CT scan. For apparently new
lesions unobserved on pretreatment or other posttreatment
scans, PET/CT was performed to confirm disease progres-
sion. Toxicity was assessed from the first dose to 4 weeks fol-
lowing the last BV dose and adverse events were graded
using ver. 4.0.3 of the National Cancer Institute Common
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Terminology Criteria for Adverse Events. Assessment of dis-
ease and survival status took place every 3 months per insti-
tutional standards of care and thereafter until study closure
or withdrawal of consent for patients who received at least
one dose of BV. 
2. Eligibility
There were five eligibility criteria. (1) Any subtype of his-
tologically confirmed high-CD30–expressing NHL, except
ALCL. High CD30 expression was defined as membranous
CD30 expression in ! 30% of tumor cells detectable by visual
assessment of routine immunohistochemistry staining using
the anti-CD30 antibody on biopsy at the time of diagnosis or
relapse. (2) A bidimensionally measurable lesion ! 1.5 cm in
the greatest transverse diameter. (3) Age 20-75 years and an
Eastern Cooperative Oncology Group performance status of
" 2. (4) Adequate bone marrow and organ function. (5) No
history of another active cancer within the previous 5 years
except basal cell carcinoma. Note that patients who had 
relapsed after autologous stem cell transplantation (SCT)
were considered eligible. Exclusion criteria were: undergoing
allogeneic SCT; active infection, human immunodeficiency
virus infection, or hepatitis B or C; and lymphomatous 
involvement of the central nervous system. The 30% cutoff
was established by consensus during an investigation initia-
tion meeting of the pathologists from each of the study sites
after they reviewed various cutoff values for ‘positive’ and
‘strong positive’ of CD30 expression across various subtypes
of NHL [4-12].
3. Statistical analysis
Sample size was calculated to reject the null with a 20%
overall disease control rate but increased to favor of a target
rate of 40% with significance 0.05 and power 80% using
Simon’s Minimax two-stage design [22]. Thus, if the rate was
less than 4/18 during the first stage, the study would be
stopped. If not, patient recruitment would be continued until
n=33. Patients’ clinical characteristics, demographics, and
treatment outcomes were analyzed based on the NHL sub-
type, and chi-squared tests were used to evaluate their rela-
tionships with outcomes. OS was calculated from the first
date of BV infusion to final follow-up or death from any
cause. PFS was calculated from the first date of BV infusion
to the date of disease progression or death from any cause.
Median potential follow-up time with 95% confidence inter-
val (CI) was determined using the Kaplan-Meier method
[23]. Survival was estimated based on Kaplan-Meier curves
and compared using the log-rank test. Two-sided p < 0.05
was considered statistically significant.
4. Biomarker analysis
Quantified CD30 expression from tumor cells was com-
pared with determined response to BV. Immunohistochem-
istry was performed on 4-µm paraffin sections following
routine protocols using a fully automated platform at each
institute; CD30 was detected using a ready-to-use antibody
(clone BerH2, Dako, Carpinteria, CA). EBV in situ hybridiza-
tion and MUM1 expression were analyzed in patients who
had tissue sample available for analysis. The presence of
EBV-positive tumor cells was considered EBV positivity 
regardless of its percentage whereas MUM1-positivity was
defined as more than 30% of tumor cells were positively
stained. Immunohistochemistry for MUM1 (MUM1p, Dako)
was also performed for exploratory biomarker development.
Differences in biomarkers between responder subgroups
were compared via post-hoc analysis using the chi-square test.
5. Ethical statement
The study was conducted by the Consortium for Improv-
ing Survival of Lymphoma (CISL) in compliance with the
Declaration of Helsinki and the International Conference on
Harmonization Good Clinical Practice. The Korean Food and
Drug Administration approved this study (No. 30229), and
each study site obtained approval from their local institu-
tional review board. All patients gave written informed con-




In total, 33 patients were enrolled between March 2015 and
January 2017 from five hospitals belonged to the CISL. Their
median age at enrollment was 56 years (range, 27 to 73
years); other characteristics at enrollment are summarized in
Table 1. Stage III/IV patients accounted for 79% (26/33) of
the sample and 70% had elevated levels of serum lactate 
dehydrogenase. All patients were treated with at least one
line of salvage chemotherapy. The median number of prior
therapies was three (range, 2 to 10) and seven patients relap-
sed after autologous SCT. At enrollment, 10 patients had 
relapsed after their last chemotherapy and 22 were refractory
after previous treatment (Table 1). The most common sub-
types were DLBCL (n=12) including one patient with relap-
sed DLBCL who was initially diagnosed with angioimmu-
noblastic T-cell lymphoma (AITL) and peripheral T-cell lym-
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phoma not otherwise specified (PTCL-NOS; n=8); other sub-
types included ENKTL (n=7), PMBCL (n=3), transformed MF
(n=2), and AITL (n=1). The median percentage of CD30-pos-
itive tumor cells was 50% (range, 30% to 100%), and 60% of 
patients (n=20) had ! 50% of CD30 expression (Table 1). 
2. Efficacy
Twelve patients achieved CR (n=6) or PR (n=6) and four
patients’ best response was SD; thus, the overall disease con-
trol rate was 48.5% (16/33). However, the remaining 17 pati-
ents were dropped due to early progressive disease after the
first or second BV cycle. Among 12 patients with CR or PR,
six (4CR, 2PR) completed 16 cycles, maintaining their res-
ponse, whereas the others showed disease progression dur-
ing treatment (Fig. 1A). A 70-year-old female patient with
PTCL-NOS discontinued the treatment because she devel-
oped a stroke prior to her second cycle. Although her res-
ponse evaluation showed SD, she could not receive further
treatment. The waterfall plot for responders showed a sig-
nificant change from baseline tumor size compared to non-
responders (Fig. 1B). The median number of treatment cycles
was two (range, 1 to 16), however, the median cycle number
for the 16 patients with CR, PR, or SD was 7.5. The overall
rates of disease control in patients with DLBCL (2CR, 2PR,
2SD; 6/12, 50%), PTCL-NOS (2CR, 1PR, 2SD; 5/8, 62.5%),
and transformed MF (2PR; 2/2, 100%) were higher compared
with those with ENKTL (1CR, 1PR; 2/7, 29%), PMBCL (1CR;
1/3, 33%), and AITL (0/1, 0%) albeit with small subtype sam-
ples (Fig. 2A). When response to BV was compared based on
disease status prior to BV, there was no significant difference
between patients with relapsed (3CR, 2PR, 1SD; 6/11, 54.5%)
and refractory disease (3CR, 4PR, 3SD; 10/22, 45.5%, p=0.721). 
3. CD30 expression in responding patients
Although we only enrolled patients with high-CD30–
expressing NHL, this sample had a wide range of CD30 
expression values (30%-100%). Based on their percentage of
CD30-positive tumor cells, patients were grouped as 30%-
49% (n=13), 50%-79% (n=9), or 80%-100% (n=11). The num-
ber of patients with CR and PR did not differ significantly
based on these groupings (46%, 6/13 vs. 11%, 1/9 vs. 46%,
5/11; p=0.182) (Fig. 2B). Nor did overall disease control rate
differ (46%, 6/13 vs. 22%, 2/9 vs. 64%, 7/11; p=0.180). 
Although transformed MF (n=2; patients 25 and 26) showed
90% and 100% CD30 expression, respectively, their best res-
ponse was PR and was not durable (Fig. 1). No other sub-
types showed a significant association between CD30 expre-
ssion and response to BV. 
Table 1. Patient characteristics at enrollment
ECOG PS, Eastern Cooperative Oncology Group perform-
ance status; LDH, lactate dehydrogenase; DLBCL, diffuse
large B-cell lympho-ma; PMBCL, primary mediastinal
large B-cell lymphoma; PTCL-NOS, peripheral T-cell lym-
phoma not otherwise specified; ENKTL, extranodal NK/
T-cell lymphoma; AITL, angioimmunoblastic T-cell lym-
phoma; MF, mycosis fungoides.
Characteristic No. (%)
Age (yr)
" 60 23 (69.7)








Stage I/II 1/6 (21.2)










Autologous stem cell transplantation
Done 7 (21.2)
Not done 26 (78.8)
No. of previous treatments 
" 3 24 (72.7)
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4. Survival outcome
With a median follow-up of 29.2 months (95% CI, 28.7 to
29.7 months), eight patients were alive and their best res-
ponses were 4CR, 3PR, and 1PD. Among these, two patients
(patients Nos. 13 and 16) maintained CR without any evi-
dence of disease relapse. Five responders (2CR, 3PR) showed
relapse or disease progression during treatment or after com-
Fig. 1.  (A) Swimmer plot for clinical course and duration of response in all patients. (B) Waterfall plot of percent change
from baseline tumor size in all patients. DLBCL, diffuse large B-cell lymphoma; PMBCL, primary mediastinal B-cell lym-
phoma; PTCL-NOS, peripheral T-cell lymphoma not otherwise specified; AITL, angioimmunoblastic T-cell lymphoma; tMF,
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Fig. 2.  (A) Response within each subtype. (B) Comparison of response based on percentage of CD30-positive tumor cells.
(C) Progression-free survival (PFS) and overall survival (OS) for 33 patients. (D) OS between responders and nonresponders.
(E) OS between relapsed and refractory patients. (F) OS based on percentage of CD30-positive tumor cells. DLBCL, diffuse
large B-cell lymphoma; PMBCL, primary mediastinal B-cell lymphoma; PTCL-NOS, peripheral T-cell lymphoma not other-
wise specified; ENKTL, extranodal natural killer/T-cell lymphoma; CR, complete response; PR, partial response; SD, stable
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pletion of 16 cycles; however, they were alive because of res-
cue by subsequent chemotherapies, including one case of
transformed MF (patient 26) who received allogeneic SCT
(Fig. 1). The one patient with ENKTL showing early PD 
(patient 27) was alive after responding to salvage treatments.
Thus, the median duration of objective response (CR and PR)
was 6.0 months (range, 3.9 to 35.0 months). However, the 
remaining patients died and the majority showed early PD
after the first or second cycle of BV. As a result, the median
PFS and OS for all patients were 1.9 months (95% CI, 0.6 to
3.2 months) and 6.1 months (95% CI, 4.5 to 7.7 months), 
respectively (Fig. 2C). OS among patients responding to BV
was significantly better than that of patients with SD or PD
(Fig. 2D). Although not statistically significant, the survival
outcome among patients who were refractory to previous
treatments prior to BV was inferior to that of patients with
Adverse event
Safety analysis population (n=33)
Total Grade 1/2 Grade 3/4
Most common adverse events ( 20%)
Fever 13 (39.3) 9/3 (36.3) 1/1 (6.0)
Neutrophil count decreased 10 (30.3) 3/7 (30.3)
Peripheral sensory neuropathy 9 (27.3) 8/1 (27.3)
Fatigue 8 (24.2) 2/3 (15.1) 3/0 (9.1)
Nausea 7 (21.2) 2/3 (15.1) 2/0 (6.0)
Platelet count decreased 7 (21.2) 1/0 (3.0) 2/4 (18.2)
Abdominal pain 7 (21.2) 2/3 (15.1) 2/0 (6.0)
Common adverse events ( 10%)
Diarrhea 6 (18.1) 3/3 (18.1) -
Vomiting 6 (18.1) 2/3 (15.1) 1/0 (3.0)
Anorexia 6 (18.1) 2/3 (15.1) 1/0 (3.0)
Edema (facial, periorbital, or leg) 5 (15.1) 2/2 (12.1) 1/0 (3.0)
Myalgia 5 (15.1) 2/3 (15.1) - 
Skin rash 5 (15.1) 2/2 (12.1) 1/0 (3.0)
Anemia 4 (12.1) 0/1 (3.0) 3/0 (9.1)
Rhinosinusitis 4 (12.1) 0/3 (9.1) 1/0 (3.0)
Upper respiratory infection 4 (12.1) 2/2 (12.1) - 
ALT/AST increased 4 (12.1) 2/0 (6.0) 1/1 (6.0)
Pruritus 4 (12.1) 2/2 (12.1) - 
Less common events ( 5%)
Dyspnea 3 (9.0) 1/1 (6.0) 1/0 (3.0)
Sore throat 3 (9.0) 1/2 (9.0) -
Cough 3 (9.0) 1/2 (9.0) -
Febrile neutropenia 2 (6.0) 2/0 (6.0)
Abdominal distension 2 (6.0) 1/1 (6.0) - 
Oral mucositis 2 (6.0) 1/0 (3.0) 1/0 (3.0)
Herpes zoster 2 (6.0) 1/1 (6.0) -
Creatinine increased 2 (6.0) 1/1 (6.0) -
Back pain 2 (6.0) 0/1 (3.0) 1/0 (3.0)
Neck pain 2 (6.0) 1/1 (6.0) -
Dizziness 2 (6.0) 1/1 (6.0) -
Headache 2 (6.0) 1/1 (6.0) -
Urinary frequency 2 (6.0) 1/1 (6.0) -
Laryngospasm 2 (6.0) 0/2 (6.0) -
Anxiety/Depressive mood 2 (6.0) 2/0 (6.0)
Chest pain 2 (6.0) 1/0 (3.0) 1/0 (3.0)
(Continued to the next page)
Table 2. Adverse events
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relapsed disease after a previous treatment (Fig. 2E). How-
ever, OS did not differ based on CD30 expression (30%-49%
vs. 50%-79% vs. ! 80%) (Fig. 2F). Nor did OS differ between
subtypes, although these samples were small (data not
shown). 
5. Adverse events
Treatment-emergent adverse events were reported in 31
patients (93.9%), all of which are summarized in Table 2.
Grade 3 or worse adverse events occurred in 23 patients
(69.7%). Serious adverse events were reported in 18 patients
(54.5%); the most common serious adverse event was fever
(n=4). Other serious adverse events included herpes zoster
(n=2), urinary tract infection (n=1), sinusitis (n=1), dyspnea
(n=1), diarrhea (n=1), anorexia (n=1), and perianal abscess
(n=1). Increase in creatinine was associated with tumor lysis
syndrome (n=1). Suicide attempt occurred in one patient 
(patient 11) after the first cycle; however, the patient was able
to continue receiving BV until PD. Patient No. 19's serious 
adverse event, stroke, led to study discontinuation (Fig. 1).
The remaining three patients were admitted to the hospital
due to disease progression during the study. The most com-
mon adverse events, occurring in ! 20% of patients, included
fever (39%), neutropenia (30%), fatigue (24%), and peripheral
sensory neuropathy (27%) (Table 2). Gastrointestinal symp-
toms, including diarrhea, nausea, and vomiting were also
commonly observed, and upper respiratory infection, rhinos-
inusitis, and skin rash were common adverse events in ! 10%
of patients (Table 2). 
6. Biomarker analysis for predicting outcome of BV treat-
ment
EBV positivity was not significantly associated with the
percentage of CD30 expression in the analysis of 29 patients
with available EBV status (Fig. 3A). MUM1 expression was
assessed by immunohistochemistry in 24 patients whose
tumor tissue was available for study. Nine patients showed
negativity for MUM1 (DLBCL 1, PMBCL 1, PTCL 3, and
ENKTL 4) whereas the remaining 15 patients were positive
for MUM1 (DLBCL 9, PMBCL 2, PTCL 2, and ENKTL 2).
MUM1 negativity was more common in 30%-49% of CD30
expression whereas MUM1-negative cases were not obser-
ved in 80%-100% of CD 30 expression (Fig. 3B). Among nine
patients negative for MUM1, five responded to BV (4CR,
1PR, 55.6%), whereas only two responded to BV (1CR, 1PR,
13.3%) out of the 15 MUM1-positive patients (Fig. 3C). 
Although their association with response was not statistically
significant (p=0.061), the PFS and OS of MUM1-negative 
patients were significantly higher compared with MUM1-
positive patients (Fig. 3D and E). When response was com-
pared based on EBV positivity of tumor cells, using 29 pati-
ents with available EBV status, the response to BV among 
patients with EBV-positive tumor (35.3%, 6/17) did not differ
significantly from those with EBV-negative tumors (25.0%,
3/12; p=0.694). Accordingly, OS did not differ between EBV-
positive and -negative patients (p=0.588) (Fig. 3F). 
Adverse event
Safety analysis population (n=33)
Total Grade 1/2 Grade 3/4
Rare events (1 case reported)
Constipation 1 (3.0) 0/1 (3.0)
Dyspepsia 1 (3.0) 0/1 (3.0)
Hemorrhoid bleeding 1 (3.0) 1/0 (3.0)
Perianal abscess 1 (3.0) 0/1 (3.0)
Gout 1 (3.0) 1/0 (3.0)
Urinary tract infection 1 (3.0) 1/0 (3.0)
Hypocalcemia 1 (3.0) 0/1 (3.0)
Stroke 1 (3.0) 1/0 (3.0)
Insomnia 1 (3.0) 0/1 (3.0)
Suicide attempt 1 (3.0) 0/1 (3.0)
Hoarseness 1 (3.0) 1/0 (3.0)
Pneumonia 1 (3.0) 1/0 (3.0)
Phlebitis 1 (3.0) 0/1 (3.0)
Values are presented as number (%). ALT, alanine transaminase; AST, aspartate aminotransferase.
Table 2. Continued
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7. Heterogeneity of response
Patients’ best responses could be clearly identified by PET/
CT because patients achieving CR showed complete disap-
pearance of FDG uptake (Fig. 4A and B). However, some 
patients showed heterogeneous responses of involved sites.
For example, one patient with PTCL (patient No. 18) showed
PR after the second cycle (Fig. 4C). His remaining target 
lesions disappeared after the 12th cycle, although new lesions
appeared. He continued to receive BV, based on the investi-
gator’s decision; however, PD was discovered 2 months after
the completion of planned treatment. Two patients (patients
Nos. 3 and 4) with DLBCL showed PD after the second cycle
of BV, although their responses differed according to the sites
involved, with several lesions disappearing and others pro-
gressing (Fig. 4D and E). 
Fig. 3.  (A) Epstein-Barr virus (EBV)–positive patients based on percentage of CD30-positive tumor cells. (B) Multiple mye-
loma oncogene 1 (MUM1)–negative patients based on percentage of CD30-positive tumor cells. (C) Response to brentuximab
vedotin by MUM1-negative and -positive patients. (D, E) Overall survival (OS) and progression-free survival (PFS) of MUM1-
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Fig. 4.  (A, B) Patients who achieved complete response (CR) with complete disappearance of fluorine-18 deoxyglucose 
uptake. (C) Patient with peripheral T-cell lymphoma (PTCL) showing partial response (PR) after the second cycle. His 
remaining target lesions disappeared after the 12th cycle (red dotted line), although new lesions appeared (yellow dotted
line). (D, E) Two patients showed progressive disease (PD) after their second cycle of brentuximab vedotin. Their responses
differed based on site because several lesions disappeared (red dotted line) while others progressed (yellow dotted line).
MUM1, multiple myeloma oncogene 1; ENKTL, extranodal natural killer/T-cell lymphoma. DLBCL, diffuse large 
B-cell lymphoma.
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Discussion
The study purpose was to determine the overall disease
control rate from BV administration among heavily pre-
treated relapsed or refractory patients with various subtypes
of NHL, other than ALCL and HL. Because our study sample
was included based on CD30-positive tumor cells being 
! 30%, regardless of histologic subtype, patients with various
subtypes of NHL, from DLBCL to MF, could be enrolled.
Considering the study population would be relapsed or refr-
actory patients who were heavily pretreated with intensified
cytotoxic chemotherapies, we thought the achievement of SD
could be beneficial for those patients who did not have few
options for alternative treatment. That was why we desig-
nated the overall disease control rate as a primary endpoint
instead of objective response rate. Our hypothesis was that
CD30 expression–based BV administration would improve
the treatment outcome. Although the overall response rate
of 36% (12/33) was lower than expected, the overall disease
control rate (48.5%, 16/33) satisfied the primary endpoint
(40%). Furthermore, six patients maintained their response
up to 12 months and could complete the planned number of
treatment cycles (Fig. 1A). When our results were compared
with that of previous studies for patients with aggressive
NHL, the median duration of responders (6.0 months) was
comparable to that of previous studies (Table 3). However,
the median PFS for all patients (1.9 months) was shorter than
that of previous studies with DLBCL (4.0 months), and PTCL
(2.6 months), and the different nature of our study popula-
tion including ENKTL might be associated with relatively
poorer outcome than previous studies [6,7]. Although only
two patients with transformed MF were enrolled in our
study, they all showed PR. This favorable outcome of our
study was consistent with the phase III study demonstrating
superior efficacy of BV to physician's choice for CD30-posi-
tive cutaneous T-cell lymphoma [24]. However, the relatively
low response rate of the CD30 expression-based BV admin-
istration in our study suggested that the extent of CD30 
expression might not predict the response to BV. Thus, the
outcome from BV may be independent of CD30 expression
in consistent with previous studies.
Table 3.  Comparison of brentuximab vedotin for relapsed or refractory aggressive non-Hodgkin lymphoma
Values are presented as median (range) or number (%). DLBCL, diffuse large B-cell lymphoma; PTCL, peripheral T-cell lym-
phoma; PMBCL, primary mediastinal large B-cell lymphoma; NOS, not otherwise specified; EBV, Epstein-Barr virus; AITL,
angioimmunoblastic T-cell lymphoma; ENKTL, extranodal NK/T-cell lymphoma; MF, mycosis fungoides; ECOG PS, Eastern
Cooperative Oncology Group performance status; ASCT, autologous stem cell transplantation; CR, complete response.
Variable DLBCL [6] PTCL [7] PMBCL [8] Present study
No. 49 ( 35 ( 15 ( 33 (
Age (yr) 62 (17-85) 64 (33-83) 29 (19-73) 56 (27-73)
DLBCL-NOS 43 ( - - 12 (
EBV-positive DLBCL 5 ( - - -
T-cell–rich B cell 1 ( - - -
PMBCL - - 15 ( 3 (
PTCL - 22 ( - 8 (
AITL - 13 ( - 1 (
ENKTL - - - 7 (
Transformed MF - - - 2 (
ECOG PS 0/1 45 (91.8) 30 (85.7) Not reported 33 (100)
CD30+ cell 25 (0-100) Not reported Not reported 30 (30-100)
Stage III/IV 35 (71.4) 27 (77.1) 8 (53.3) 26 (79)
Refractory to most recent prior therapy 40 (81.6) 22 (62.8) 11 (73.3) 22 (67)
No. of previous treatments 3 (1-6) 2 (1-9) 3 (1-4) 3 (2-10)
Previous ASCT 10 (20.4) 3 (9) 8 (53) 7 (21.2)
Disease control rate 32/48 (66.7) 20/34 (58.8) 3/15 (20.0) 16/33 (48.4)
Objective response rate 21/48 (43.7) 14/34 (41.1) 2/15 (13.3) 12/33 (36.3)
CR rate 8/48 (16.7) 8/34 (23.5) 0 ( 6/33 (18.1)
Progression-free survival (mo) 4.0 (0.6-24) 2.6 (not reported) - 1.9 (0.4-35.0)
Duration of response (mo) 5.6 (0.0-22.7) 7.6 (1.3-14) < 3-4 6.0 (3.9-35.0)
Duration of complete response (mo) 16.6 (2.7-22.7) Not reported - 11.3 (4.5-35.0)
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There are several potential explanations for this unexpect-
edly poor outcome among patients with CD30 expression 
! 30%. First, the immunohistochemistry for CD30 used
tumor samples available to the study at patient enrollment.
Thus, some patients’ samples were from their diagnosis
whereas others’ were from their point of relapse or progres-
sion. Possible changes in CD30 expression from diagnosis to
relapse might influence BV-based outcomes. Second, CD30
could be expressed heterogeneously depending on site 
although we could not perform multiple biopsies in the same
patient. If we could evaluate the extent of CD30 expression
in different sites of the same patients, the patterns of CD30
expression might differ, possibly leading to different res-
ponse patterns to BV. Indeed, disease progression was 
observed even when the target lesion disappeared (Fig. 4).
Third, the downregulation of CD30 expression could be 
related to disease progression during treatment. An in vitro
study using the ALCL cell line Karpas-299 showed a reduc-
tion in the percentage of CD30-positive cells after long-term
BV treatment [25]. Thus, continuous BV treatment may 
induce downregulation of CD30 expression in tumor cells,
leading to drug resistance. In fact, we observed several cases
showing disease progression during treatment even though
they initially showed response to BV (Fig. 1). Another mech-
anism of resistance to antibody-drug conjugate is the expres-
sion of drug exporter proteins such as multidrug-resistance
protein 1 (MDR1) [25]. Because monomethyl auristatin E is a
chemotherapeutic drug affected by MDR1, a drug efflux pro-
tein, this may have contributed to the poor outcome from BV
seen in this study. Inhibition of MDR1 has been reported to
overcome resistance to BV and show synergism with BV in
a mouse xenograft model [26]. A recent phase I study com-
bining cyclosporine, an MDR1 inhibitor, with BV showed an
overall response rate of 67% (CR 33%) in primary BV refrac-
tory HL patients. These results might support the role of
MDR1 in the resistance to BV [27]. Considering that ENKTL
tumor cells are well known to express MDR1, the unsatisfac-
tory outcome of ENKTL could be explained by MDR1 expre-
ssion of tumor cells although we did not evaluate the MDR1
expression of ENKTL patients participating in this study [28].
In a post-hoc analysis to explore biomarkers predicting res-
ponse to BV, EBV positivity was not significantly associated
with the percentage of CD30 expression, whereas MUM1
negativity was more common in 30%-49% of CD30 expres-
sion, and MUM1-negative cases were not observed in 80%-
100% of CD30 expression (Fig. 3A and B). This indicates that
EBV positivity may be a cause of CD30 expression, although
it may not be related to the extent of CD30 expression. How-
ever, as MUM1 expression could be activated by CD30 throu-
gh NF-!B activation, all cases with > 80% of CD30 expression
showed MUM1 positivity while MUM1-negative cases were
observed in cases with < 50% of CD30 expression (Fig. 3B).
Accordingly, EBV positivity was unrelated to response to BV,
whereas MUM1 expression showed a tendency toward asso-
ciation with response to BV (Fig. 3C). Furthermore, the OS
and PFS of MUM1-negative patients were significantly better
than those of MUM1-positive patients (Fig. 3D and E). Given
that this analysis was based on 24 patients with DLBCL,
PMBCL, PTCL, and ENKTL, which usually follow aggressive
courses after relapse, our findings suggest that MUM1 status
may serve as a parameter for predicting both response to BV
and survival outcome after BV treatment. Further, our study
showed low frequency of MUM1 expression in ENKTL com-
pared with PTCL, which is consistent with our previous
study [29]. Thus, the poor response to BV in ENKTL patients
of our study might be more related to aforementioned MDR1
expression rather than MUM1 because MDR1 expression is
common in ENKTL. However, the association of MDR1 with
the response to BV in various subtypes of NHL should be
evaluated by additional studies because MDR1 can be expre-
ssed and cause resistance to chemotherapy in other subtypes,
especially EBV-positive T-cell lymphoproliferative disorders
[30].
In this study, the most common adverse events, occurring
in ! 20% of patients, included fever (39%), neutropenia (30%),
fatigue (24%), and peripheral sensory neuropathy (27%),
which is consistent with previous studies [31,32]. Other side
effects, such as gastrointestinal symptoms and upper respi-
ratory infection, were manageable. Although several cases
showed central nervous system toxicity and required man-
agement, including one suicide attempt after the first cycle,
these were all manageable. Thus, the trial’s safety profile was
comparable with previous experiences with BV and the side
effects that occurred were not problematic during treatment,
despite our enrollment of heavily pretreated patients with
relapsed or refractory lymphomas. This manageable safety
profile of BV in relapsed or refractory lymphoma suggested
it could be combined with other chemotherapeutic drugs
having non-overlapping toxicity. Indeed, a recent phase III
study for patients with CD30-positive PTCL showed a sig-
nificantly improved survival with manageable safety profile
in patients receiving the front-line treatment of BV plus CHP
(cyclophosphamide, doxorubicin, and prednisone) compa-
red to patients treated with CHOP (cyclophosphamide, dox-
orubicin, vincristine, and prednisone) [33].
In conclusion, the single-agent activity of BV was accept-
able in terms of disease control rate and toxicity profiles in
patients with relapsed or refractory high-CD30–expressing
NHL. However, administration of BV among patients selec-
ted on the basis of CD30 expression did not improve their
treatment outcomes compared with previous studies. Out-
comes from BV treatment may be independent of CD30 
expression, and poor outcome among patients with ENKTL
might be related to MDR1 expression of tumor cells. Consid-
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ering the association between improved outcomes in MUM1-
negative patients irrespective of CD30 expression extent,
MUM1 negativity might be a biomarker predicting outcome
of BV in CD30-positive lymphomas. Further studies with
larger samples are warranted to confirm the results of this
phase II study.
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